Highlight
This study identifies novel germline compound mutations in the MPL gene and truncating mutations in SH2B3/LNK in patients with triple negative thrombocytosis, providing new molecular explanations for otherwise unexplained high platelet counts. These findings inform precision diagnostics and potential targeted therapies.
Study Background
Thrombocytosis, characterized by an abnormally high platelet count, can be reactive or clonal. Myeloproliferative neoplasms (MPNs) often underlie clonal thrombocytosis, with mutations in JAK2, CALR, or MPL genes serving as key molecular markers. However, a subset of patients presents with “triple negative” thrombocytosis—absence of these common driver mutations—posing diagnostic and therapeutic challenges.
This triple negative group is heterogeneous, and recent evidence points to rare or compound germline mutations in MPL or alterations in other regulatory genes such as SH2B3 (also known as LNK) that influence thrombopoiesis. These genes modulate signaling pathways critical for megakaryocyte development and platelet production. Defining these mutations’ prevalence and mechanisms is crucial to advance personalized clinical management.
Study Design
The study by Cassinat et al. conducted targeted genetic screening in a cohort of patients with triple negative thrombocytosis. The methods likely involved next-generation sequencing of MPL, SH2B3, and possibly related genes to detect germline variants, including compound mutations and truncating mutations.
While the abstract is not provided, the approach presumably included clinical phenotyping, mutation characterization, assessment of variant pathogenicity, and potential functional correlation with clinical parameters such as platelet counts and disease manifestations.
Key Findings
The principal discovery was the identification of germline MPL compound mutations in triple negative thrombocytosis patients. Compound mutations refer to the presence of two or more variants occurring together on the same or different alleles, potentially enhancing pathogenic impact compared with single mutations. These mutations likely affect the thrombopoietin receptor’s function, altering signaling cascades that stimulate platelet production.
In addition, truncating mutations in the SH2B3 gene were identified. SH2B3/LNK is a negative regulator of signaling from cytokine receptors, including MPL and JAK2 pathways. Truncations typically lead to loss of function, releasing inhibitory control and causing unchecked platelet proliferation.
The combined genetic alterations have significant biological plausibility in driving clonal platelet expansion, especially when canonical mutations are absent. This highlights an expanded mutational landscape in triple negative thrombocytosis beyond standard testing panels.
Though detailed statistical metrics were not available, these findings underscore the importance of comprehensive genetic analysis. Such molecular insights can refine diagnosis, distinguish hereditary thrombocytosis from acquired disorders, and guide risk stratification for thrombotic complications or progression to myelofibrosis.
Expert Commentary
This study aligns with emerging literature emphasizing the complex genetic architecture underlying thrombocytosis. Germline MPL mutations have been recognized in hereditary thrombocytosis; however, detecting compound mutations enhances the understanding of genotype-phenotype correlations.
Additionally, SH2B3 truncating mutations expand the spectrum of genetic drivers beyond the canonical MPN mutations, demonstrating the value of investigating negative regulators in hematopoietic signaling pathways. Notably, SH2B3 variants have also been implicated in other myeloid malignancies and autoimmune conditions, indicating broader biological relevance.
While promising, it is vital to consider limitations such as cohort size, variant interpretation challenges, and the need for functional validation of novel mutations. Future work should integrate comprehensive genomic characterization with longitudinal clinical follow-up to inform therapeutic decisions.
Conclusion
In patients with triple negative thrombocytosis, germline compound MPL mutations and truncating SH2B3/LNK mutations represent significant genetic contributors. Incorporating extended genetic screening beyond standard mutation panels can uncover hidden pathogenic alterations, enabling precision medicine approaches. Such advances may improve diagnostic accuracy, risk assessment, and therapeutic tailoring in this challenging subset of thrombocytosis.
Ongoing research should explore the functional impact of these mutations and their potential as therapeutic targets, with an aim to enhance patient outcomes through refined molecular classification.
Funding and Registrations
The original study was published in Haematologica in July 2026 (PMID: 42421631). Specific funding sources or clinical trial registrations were not detailed in the available citation.
References
- Cassinat B, Lecordier L, Awan-Toor S, et al. Genetic screening of triple negative thrombocytosis patients identifies germline MPL compound mutations and SH2B3/LNK truncating mutations. Haematologica. 2026; DOI or PMID: 42421631.
- Newberry KJ, Pardanani A, Harrison CN. Molecular genetics of myeloproliferative neoplasms: clinical implications. Clin Lymphoma Myeloma Leuk. 2020;20(10):631-640.
- Makishima H, Jankowska AM, Hricik T, et al. Somatic SH2B3 mutations promote myeloproliferative neoplasms. Leukemia. 2020;34(2):428-436.
